trastuzumab deruxtecan
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients
The test is intended to identify metastatic breast cancer patients with low HER2 expression who could benefit from treatment with Enhertu.
The test is intended to identify metastatic breast cancer patients with low HER2 expression who could benefit from treatment with Enhertu.